Actively Recruiting

Age: 18Years - 75Years
MALE
NCT05116579

Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)

Led by Sun Yat-sen University · Updated on 2024-09-05

30

Participants Needed

1

Research Sites

200 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To evaluate the application value of customized ctDNA monitoring in efficacy assessment and prediction during PARPi treatment

CONDITIONS

Official Title

Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)

Who Can Participate

Age: 18Years - 75Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male patients aged 18 to 75 years
  • Histologically or cytologically confirmed prostate adenocarcinoma with homologous recombination deficiency or DDR gene mutation
  • Documented metastatic castration-resistant prostate cancer with planned PARP inhibitor treatment
  • Measurable target lesion visible on imaging studies
  • Available adequate tumor tissue sample collected before any treatment with specific quality criteria
  • ECOG performance status of 0 to 1
  • Estimated survival time of 12 weeks or more
  • Willing and able to provide informed consent
Not Eligible

You will not qualify if you...

  • Currently receiving other anti-tumor therapies such as chemotherapy or immunotherapy
  • Organ transplantation within the last 3 months
  • Autoimmune diseases or history of HBV, HCV, or HIV infection (acute or chronic)
  • Presence of pneumonia
  • Severe concurrent illnesses or co-morbid conditions making participation unsuitable
  • Unwilling or unable to provide informed consent
  • Judged unsuitable for trial participation by investigators

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China, 510060

Actively Recruiting

Loading map...

Research Team

Y

Yonghong Li, M.D.

CONTACT

J

Jun Wang, M.D.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi) | DecenTrialz